Research programme: enzyme replacement therapies - Chiesi Farmaceutici
Alternative Names: ERT - ChiesiLatest Information Update: 22 Feb 2021
At a glance
- Originator Chiesi Farmaceutici
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lysosomal storage diseases
Most Recent Events
- 01 Feb 2021 Preclinical trials in Lysosomal storage diseases in Italy and USA before February 2021 (Chiesi Farmaceutici pipeline, February 2021)